Johnston 1995

Methods	ALLOCATION CONCEALMENT: unclear BLINDING: at least one measure was assessed by an independent assessor blind to treatment allocation
Participants	DIAGNOSIS: DSM‐III agoraphobia AGE: mean=37 years SEX: 100% women HISTORY: mean duration of illness=9.5 years PSYCHIATRIC COMORBIDITY: ‐ MEDICAL COMORBIDITY: ‐
Interventions	ACUTE PHASE: 17 weeks 1. clomipramine (mean=95 mg/d) + behavior therapy (twice weekly for eight weeks) 2. clomipramine alone 3. placebo + behavior therapy 4. placebo alone ACUTE PHASE CO‐INTERVENTION: not specified MAINTENANCE: 12 weeks On clomipraime or placebo only; no psychological intervention MODE OF DISCONTINUATION: naturalistic FOLLOW‐UP: ‐
Outcomes	RESPONSE: >=50% reduction in FQ‐AG [imputed from mean&SD] REMISSION: ‐ GLOBAL: ‐ PANIC ATTACK: Number of days per week when panic was reported AGORAPHOBIA: FQ‐Ag, FSS‐III‐Ag, BAT GENERAL ANXIETY: ‐ DEPRESSION: SCL‐90‐R Depression FUNCTIONING: SAS‐SR Social Leisure
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear